Rather than focusing on a single condition, Countdown invests across six research pillars that together reflect the full landscape of mitochondrial medicine — from understanding how cellular energy shapes human health, to detecting dysfunction earlier, to advancing the next generation of therapeutics and interventions.
Each pillar was chosen not only for its individual scientific importance, but for how it advances the field as a whole.
Early detection and diagnostics create the tools needed to identify dysfunction sooner, track health over time, guide treatment, and support more proactive and preventive approaches to care.
Research in primary mitochondrial and rare genetic disease helps uncover core biological mechanisms that may have implications far beyond a single condition.
Research in brain and mental health, along with women’s health, helps deepen our understanding of how mitochondrial dysfunction may shape some of the most pressing and underexplored areas of modern human health.
Research in chronic disease and aging helps connect mitochondrial science to the conditions affecting millions of people worldwide, while advancing our understanding of the role mitochondrial dysfunction may play across many of the diseases impacting modern human health.
Frontier therapeutics and innovation ensure we continue investing in what is next — supporting bold ideas, emerging technologies, and new approaches that have the potential to transform the future of medicine.
Principal Investigator: James McCully, PhD — Boston Children’s Hospital / Harvard Medical School
Grant Awarded: February 2026 | Funding Lens: Advanced Therapeutics & Frontier Innovation; Chronic Disease & Aging
This project advances mitochondrial transplantation, a pioneering therapeutic strategy that restores cellular energy by delivering healthy mitochondria directly into damaged muscle tissue.
Isolated healthy mitochondria are injected into compromised muscle, where they integrate into host cells and reestablish energy production, metabolic signaling, and cellular resilience.
Dr. McCully’s laboratory has demonstrated safety and functional benefit in both cardiac and skeletal muscle, including clinical application in pediatric cardiac patients. CFAC funding now extends this work into a validated Duchenne Muscular Dystrophy (DMD) genetic mouse model. Because muscle tissue is highly energy-dependent and DMD is marked by chronic inflammation, oxidative stress, mitochondrial dysfunction, and impaired calcium handling, restoring mitochondrial function has the potential to improve muscle cell survival, reduce inflammation, strengthen cardiac performance, and slow disease progression.
Principal Investigator: Elias Adriaenssens, PhD — Research Institute of Molecular Pathology (IMP) | Grant Awarded: February 2026
Funding Lens: Advanced Therapeutics & Frontier Innovation; Chronic Disease & Aging; Primary Mitochondrial & Rare Disease
Damaged mitochondria accumulate in neurodegeneration, primary mitochondrial disorders, and aging. When cellular clearance pathways fail, dysfunctional mitochondria persist, contributing to neuronal injury and progressive decline. For years, scientists have known something remarkable: when the body is deprived of oxygen, cells activate a powerful self-repair program. In people with Parkinson’s, rare mitochondrial diseases, and a wide range of chronic conditions, this kind of cellular renewal could be transformative. The problem is getting there safely.
Dr. Adriaenssens works on a molecular complex that acts as a brake on one of the cell’s mitochondrial clearance pathways, one that is activated by hypoxia. By studying this complex, the team aims to identify the precise molecular targets needed to release that brake selectively, activating mitochondrial renewal without any systemic oxygen deprivation.
Because sustained low oxygen is not a safe or practical therapy, the objective is to isolate the precise mitochondrial pathways responsible for these benefits and define their molecular “on-off” mechanisms. The goal is to therapeutically mimic the protective effects of hypoxia without reducing oxygen levels.
Newly awarded in February 2026, updates will be shared as the research progresses.
By identifying molecular switches that safely activate beneficial stress-response pathways, this work could enable therapies that restore mitochondrial health across primary mitochondrial disease, neurodegeneration, cancer, and aging without the systemic risks of hypoxia itself.
Principal Investigators: Noa Sher, PhD — University of Haifa; CSO, Minovia Therapeutics; Natalie Yivgi-Ohana, PhD — CEO, Minovia Therapeutics
Grant Awarded: August 2025 | Funding Lens: Early Detection & Precision Diagnostics
This project is developing standardized, blood-based mitochondrial scoring tools capable of measuring mitochondrial function, quality, and content.
Using a defined biomarker panel, the team generates “MitoScores” designed to distinguish health from disease and establish reference ranges that can support clinical decision-making. The long-term vision is to integrate mitochondrial assessment into routine checkups, transforming mitochondrial health into a measurable, actionable diagnostic category.
Minovia has opened its mitochondrial biomarker clinical trial at Sheba Medical Center. The study is now enrolling patients with primary mitochondrial disease alongside healthy volunteers, and blood samples are actively being processed in Haifa laboratories. MitoScores are being generated to define reference ranges that distinguish mitochondrial dysfunction from health.
In parallel, Minovia’s lead investigational therapy, MNV-201, received FDA Fast Track and Orphan Drug Designations in myelodysplastic syndrome, reinforcing regulatory momentum around its mitochondrial platform. The company has also secured two new U.S. patents supporting its Mitochondrial Augmentation Therapy (MAT) platform.
Measurement infrastructure is foundational to therapeutic progress. By standardizing mitochondrial biomarkers, this project provides the diagnostic backbone for the broader mitochondrial ecosystem, enabling earlier detection, better patient stratification, and more precise evaluation of emerging therapies. This work positions mitochondrial scoring to evolve from a research tool into a routine clinical diagnostic with the potential to become a household measure of cellular health.
Principal Investigator: Anupam Patgiri, PhD — Emory University | Grant Awarded: September 2024
Two-Lens Strategy: Rare & Primary Mitochondrial Disease; Chronic Disease & Aging
The electron transport chain (ETC) produces most of the cell’s ATP. In mitochondrial disease, inherited ETC mutations disrupt electron flow, causing toxic electron accumulation (NADH-reductive stress) and energy failure in high-demand organs such as the brain and heart.
There are currently no FDA-approved therapies that broadly address this core biochemical dysfunction. Importantly, similar electron transport disruptions are also implicated in cancer metabolism and neurodegenerative diseases such as Parkinson’s disease.
Dr. Patgiri’s team engineered a first-in-class therapeutic protein called LOXCAT, designed to safely reroute excess electrons when mitochondrial energy production is impaired.
When administered into the bloodstream, LOXCAT transfers excess electrons from circulating metabolites to oxygen, reducing toxic buildup across multiple organs. In effect, it functions as an artificial electron transport pathway in the blood, restoring redox balance and supporting the cellular metabolism systemically.
While strategically positioned to address primary mitochondrial disease, LOXCAT has also been tested in models relevant to cancer and Parkinson’s disease, demonstrating broader translational potential.
In preclinical studies, LOXCAT reduced toxic electron accumulation in the brain and heart of mitochondrial disease models.
The team is now improving the protein’s durability in circulation and developing a gene-therapy version that could enable long-term therapeutic benefit from a single treatment.
LOXCAT targets a shared biochemical consequence across multiple mitochondrial mutations: excess electron buildup.
By anchoring in rare mitochondrial disease while addressing a mechanism relevant to cancer, neurodegeneration, and aging, this project reflects
Countdown’s two-lens strategy funding rare disease breakthroughs with broad systemic impact.
Principal Investigators: Barry Byrne, MD, PhD — University of Florida; Madhurima Saha, PhD — University of Florida; Deborah Murdock, PhD — University of Pennsylvania / Children’s Hospital of Philadelphia | Grant Awarded: 2024 | Funding Lens: Primary Mitochondrial & Rare Genetic Disease
This project advances a viral gene replacement strategy designed to restore functional MECR expression in validated disease models. Using an optimized viral vector platform, the therapy delivers a healthy copy of the MECR gene to affected tissues, with a focus on targeting neurological involvement.
Phase I development has been completed. The team achieved robust gene expression in the brain and has advanced into efficacy studies to evaluate functional and clinical impact in disease models.
Importantly, emerging findings from MEPAN research reveal that mitochondrial lipid pathways disrupted in this rare disorder are also altered in Alzheimer’s disease, suggesting a shared mitochondrial mechanism that extends beyond rare disease.
Rare mitochondrial diseases provide structured translational pathways, defined patient populations, and regulatory clarity for gene therapy development. At the same time, insights gained from MEPAN syndrome are illuminating mitochondrial lipid mechanisms that may contribute to broader neurodegenerative conditions, reinforcing the role of rare disease as a gateway to systemic impact.
